<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Am Acad Dermatol</span><span class="iso-abbrev" title="iso-abbrev">J. Am. Acad. Dermatol</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of the American Academy of Dermatology</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">0190-9622</span><span class="issn-epub" tagx="issn" title="issn-epub">1097-6787</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">by the American Academy of Dermatology, Inc.</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7303642">7303642</a></span><span class="publisher-id" title="publisher-id">S0190-9622(20)31149-X</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1016/j.jaad.2020.06.051">10.1016/j.jaad.2020.06.051</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Review</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zahedi Niaki</span><span class="given-names" tagx="given-names" title="given-names">Omid</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff1">a</a><a href="#cor1">âˆ—</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Anadkat</span><span class="given-names" tagx="given-names" title="given-names">Milan J.</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff2">b</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">Steven T.</span></span><span class="degrees" tagx="degrees" title="degrees">MD, MPH, MS-HPEd</span><a href="#aff3">c</a><a href="#aff4">d</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fox</span><span class="given-names" tagx="given-names" title="given-names">Lindy P.</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff5">e</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Harp</span><span class="given-names" tagx="given-names" title="given-names">Joanna</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff6">f</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Micheletti</span><span class="given-names" tagx="given-names" title="given-names">Robert G.</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff7">g</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nambudiri</span><span class="given-names" tagx="given-names" title="given-names">Vinod E.</span></span><span class="degrees" tagx="degrees" title="degrees">MD MBA</span><a href="#aff1">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pasieka</span><span class="given-names" tagx="given-names" title="given-names">Helena B.</span></span><span class="degrees" tagx="degrees" title="degrees">MD MS</span><a href="#aff8">h</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shinohara</span><span class="given-names" tagx="given-names" title="given-names">Michi M.</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff9">i</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rosenbach</span><span class="given-names" tagx="given-names" title="given-names">Misha</span></span><span class="degrees" tagx="degrees" title="degrees">MD</span><a href="#aff7">g</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Merola</span><span class="given-names" tagx="given-names" title="given-names">Joseph F.</span></span><span class="degrees" tagx="degrees" title="degrees">MD, MMSc</span><a href="#aff1">a</a><a href="#aff10">j</a></span><span class="citation_author_institution" id="aff1">[a], </span><span class="citation_author_institution" id="aff2">[b], </span><span class="citation_author_institution" id="aff3">[c], </span><span class="citation_author_institution" id="aff4">[d], </span><span class="citation_author_institution" id="aff5">[e], </span><span class="citation_author_institution" id="aff6">[f], </span><span class="citation_author_institution" id="aff7">[g], </span><span class="citation_author_institution" id="aff8">[h], </span><span class="citation_author_institution" id="aff9">[i], </span><span class="citation_author_institution" id="aff10">[j], </span></div> <div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">âˆ—</span>Correspondence to: Omid Zahedi Niaki, MD, 41 Avenue Louis Pasteur, 319, Boston, MA 02115.</div> </div><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-6-6</span></span><span class="pub-date-ppub" title="pub-date-ppub">ppub: <span>2020-10</span></span><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-6-6</span></span><span class="volume" tagx="volume" title="volume">83</span><span class="issue" tagx="issue" title="issue">4</span><span class="fpage" tagx="fpage" title="fpage">1150</span><span class="lpage" tagx="lpage" title="lpage">1159</span><span class="history" title="history"><span class="accepted" title="accepted">accepted: 2020-6-10</span></span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">American Academy of Dermatology, Inc.</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <p>Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Key words</div> <div class="kwd" title="kwd">
autoimmune disease</div> <div class="kwd" title="kwd">
COVID-19</div> <div class="kwd" title="kwd">
dermatology-rheumatology</div> <div class="kwd" title="kwd">
immunosuppression</div> <div class="kwd" title="kwd">
immunosuppressive therapy</div> <div class="kwd" title="kwd">
medical dermatology</div> <div class="kwd" title="kwd">
SARS-CoV-2</div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Abbreviations used</div> <div class="kwd" title="kwd">
CI, confidence interval</div> <div class="kwd" title="kwd">
COVID-19, coronavirus disease 2019</div> <div class="kwd" title="kwd">
IL, interleukin</div> <div class="kwd" title="kwd">
MERS, Middle East respiratory syndrome</div> <div class="kwd" title="kwd">
OR, odds ratio</div> <div class="kwd" title="kwd">
RR, relative risk</div> <div class="kwd" title="kwd">
SARS, severe acute respiratory syndrome</div> <div class="kwd" title="kwd">
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2</div> <div class="kwd" title="kwd">
TNF, tumor necrosis factor</div> <div class="kwd" title="kwd">
URI, upper respiratory tract</div> <div class="kwd" title="kwd">
VTE, venous thromboembolism</div> </div> </div> </div> <div class="body" title="body"> <p id="p0010"> </p><div class="boxed-text" tagx="boxed-text" title="boxed-text">  <div class="title" tagx="title" title="title">
Capsule Summary</div>  <p id="p0015"> </p><ul> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0020">This article adds to the limited literature on coronavirus disease 2019 (COVID-19) and immunosuppression. It provides expert opinion based on existing drug safety data and recent COVID-19 outcome data in patients with immune-mediated dermatologic disorders.</p> </li> <li><span class="label" tagx="label" title="label">â€¢</span><p id="p0025">The goal is to facilitate management of immunosuppressive drugs and minimize potential for harm in this patient population.</p> </li> </ul> <p /> </div> <p /> <p id="p0030">In the context of the current coronavirus diseaseÂ 2019 (COVID-19) pandemic, physicians treating patients with immune-mediated dermatologic diseases are tasked with challenging decisions when initiating immunosuppressive therapy or altering the existing regimens of their patients. This article will examine relevant systemic drug safety data obtained from clinical trials, registries, and cohort studies across disciplines to provide expert-derived guidance in the face of much uncertainty.</p> <div class="baselineriskinimmune-mediateddermatologicdisorders" title="sec"> <div class="title" tagx="title" title="title">
Baseline risk in immune-mediated dermatologic disorders</div> <p id="p0035">Evaluating the baseline infection risk of patients isÂ an important aspect of risk stratification. Several immune-mediated conditions, such as psoriasis and lupus, are associated with increased infection risk irrespective of exposure to immunomodulatory agents.<a href="#bib1"><sup>1</sup></a><sup>,</sup><a href="#bib2"><sup>2</sup></a> Many of these conditions are further associated with comorbidities known to predict poor outcomes in COVID-19 infection (eg, diabetes and obesity in patients with psoriasis, asthma in patients with atopic dermatitis, and interstitial lung disease with connective tissue disorders).<a href="#bib3"><sup>3</sup></a> Each patient presents a unique set of variables that dictate the approach to their therapy plan. A summary of these considerations is found in <a href="#tbl1">Table I</a> . <div class="table-wrap_UNKNOWN" position="float" id="tbl1"><span class="label" tagx="label" title="label">Table I</span> </div></p><p>Summary of key considerations in the shared decision-making process concerning immunosuppressive and immunomodulatory therapy during the coronavirus disease 2019 pandemic</p>  <table frame="hsides" rules="groups"> <tbody> <tr> <td> <ul> <li><span class="label" tagx="label" title="label">1.</span><p id="p0210">The severity of the underlying disease, with special consideration given to a history of flares with medication changes and potential need for emergency care.</p> </li> <li><span class="label" tagx="label" title="label">2.</span><p id="p0215">The patient's underlying risk factors (eg, comorbidities).</p> </li> <li><span class="label" tagx="label" title="label">3.</span><p id="p0220">Contextual factors impacting patient risk (eg, high-risk occupation, caregiver roles, at-risk individuals in the home or work environment, etc).</p> </li> <li><span class="label" tagx="label" title="label">4.</span><p id="p0225">The patient's preferences and level of risk tolerance.</p> </li> <li><span class="label" tagx="label" title="label">5.</span><p id="p0230">The level of exposure to health care settings dictated by the need for monitoring laboratory tests or administration of the drug (eg, infusions), or both.</p> </li> <li><span class="label" tagx="label" title="label">6.</span><p id="p0235">The relative level of immunosuppression attributed to a given therapy or combination of therapies based on available information.</p> </li> </ul> </td> </tr> </tbody> </table>  <p /> </div> <div class="learningfromthepast" title="sec"> <div class="title" tagx="title" title="title">
Learning from the past</div> <p id="p0040">COVID-19 appears to follow a disease course similar to previous highly pathogenic coronavirus infections (ie, Middle East respiratory syndrome [MERS] and severe acute respiratory syndrome [SARS]), with up to 20% of hospitalized patients progressing to potentially fatal acute respiratory distress syndrome.<a href="#bib4"><sup>4</sup></a> Risk factors for poor outcomes during the SARS and MERS outbreaks included older age and the presence of comorbidities such as obesity, diabetes, heart disease, lung disease, and renal disease. Immunosuppression alone was not identified as a significant risk factor for primary infection or death,<a href="#bib5"><sup>5</sup></a><sup>,</sup><a href="#bib6"><sup>6</sup></a> and several milder or attenuated cases of infection were reported in immunosuppressed populations.<a href="#bib7"><sup>7</sup></a><sup>,</sup><a href="#bib8"><sup>8</sup></a> Corroborating this, a National Institutes of Health-funded animal study showed that macaques immunosuppressed with cyclophosphamide had significantly lower rates of lung pathology despite active MERS-CoV infection.<a href="#bib9"><sup>9</sup></a> It has been hypothesized that severe pulmonary involvement is likely secondary to an excessive inflammatory response, characterized by macrophage hyperactivation and high levels of proinflammatory cytokines.<a href="#bib10"><sup>10</sup></a></p> <p id="p0045">It is thought that dampening the hyperinflammatory reaction outweighs the risk of temporary impairment in antiviral immunity. Numerous clinical trials are underway to examine the therapeutic potential of various immunosuppressive and immunomodulatory agents in the treatment of COVID-19 and the potential associated cytokine storm. Existing drug safety data and relevant trial data are presented below.</p> </div> <div class="dataregardinginfectionriskandcomplicationsofimmunosuppressiveandimmunomodulatoryagents" title="sec"> <div class="title" tagx="title" title="title">
Data regarding infection risk and complications of immunosuppressive and immunomodulatory agents</div> <div class="glucocorticoids" title="sec"> <div class="title" tagx="title" title="title">
Glucocorticoids</div> <p id="p0050">Evidence linking systemic corticosteroids to increased infection risk comes from a meta-analysis of 71 clinical trials, which found an increased overall rate of infection in patients receiving systemic corticosteroids (relative risk [RR], 1.6; 95% confidence interval [CI], 1.3-1.9).<a href="#bib11"><sup>11</sup></a> The risk was dose-dependent and minimal with daily doses &amp;lt;10Â mg.<a href="#bib11"><sup>11</sup></a><sup>,</sup><a href="#bib12"><sup>12</sup></a> Similarly, observational data from the large Corrona registry (Corrona, LLC, Waltham, MA) also found increased overall infection risk with prednisone &amp;gt;10Â mg/d in patients with rheumatoid arthritis (incidence rate ratio, 1.30; 95% CI, 1.1-1.5).<a href="#bib13"><sup>13</sup></a></p> <div class="therapeuticpotentialincovid-19" title="sec"> <div class="title" tagx="title" title="title">
Therapeutic potential in COVID-19</div> <p id="p0055">Data evaluating the use of systemic corticosteroids in COVID-19 are limited. Recently, the preliminary results of a large randomized controlled trial (RCT) conducted in the United Kingdom revealed reduced 28-day mortality and hospital length of stay in oxygen requiring or ventilated patients treated with dexamethasone 6 mg daily for 10 days as compared with usual care.<a href="#bib14"><sup>14</sup></a> Conversely, data from the SARS and MERS epidemics are conflicting and many studies have revealed no mortality benefit, delayed viral clearance, and evidence for harm.<a href="#bib15">15</a>, <a href="#bib16">16</a>, <a href="#bib17">17</a> A similar lack of benefit and potential for harm has been noted in other viral pneumonias, including influenza and respiratory syncytial virus.<a href="#bib18"><sup>18</sup></a><sup>,</sup><a href="#bib19"><sup>19</sup></a></p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0060">There is evidence for harm without a clear mortality benefit when systemic corticosteroids have been used to treat MERS and SARS-associated pneumonia. Existing safety data also indicates that daily doses of systemic corticosteroids &amp;gt;10 mg of prednisone equivalent are associated with an increased susceptibility to overall infection. Recently however, preliminary evidence from a large RCT suggests that the use of dexamethasone reduces mortality in hospitalized COVID-19 patients. Further data are needed to define the optimal use and potential complications of systemic corticosteroid use in the setting of COVID-19.</p> </div> </div> <div class="methotrexate" title="sec"> <div class="title" tagx="title" title="title">
Methotrexate</div> <p id="p0065">In clinical trials, methotrexate increased infection risk in patients with rheumatoid arthritis (risk ratio, 1.25; 95% CI, 1.01-1.56), compared with placebo, but not in those with other immune-mediated conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, and scleroderma.<a href="#bib20"><sup>20</sup></a> Robust data for adverse events related to methotrexate come from a recent clinical trial evaluating the efficacy of low-dose methotrexate for the treatment of atherosclerosis in patients with cardiovascular disease. Mild infections were slightly increased (hazard ratio, 1.15; 95% CI, 1.01-1.30), but there was no statistically significant increase in upper respiratory tract (URI) or influenza infections.<a href="#bib21"><sup>21</sup></a></p> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0070">A modestly increased risk of infection associated with methotrexate has been suggested in some studies. Further data are needed to understand the impact of methotrexate on SARS-CoV-2 infection.</p> </div> </div> <div class="antimalarialdrugs" title="sec"> <div class="title" tagx="title" title="title">
Antimalarial drugs</div> <p id="p0075">When used for their immunomodulatory properties, antimalarials have not been associated with infectious complications in systemic autoimmune disease,<a href="#bib22"><sup>22</sup></a><sup>,</sup><a href="#bib23"><sup>23</sup></a> and some studies even suggest their use may help prevent serious infections in systemic lupus erythematosus.<a href="#bib2"><sup>2</sup></a></p> <div class="therapeuticpotentialincovid-19" title="sec"> <div class="title" tagx="title" title="title">
Therapeutic potential in COVID-19</div> <p id="p0080">Antimalarial drugs were at the forefront of the COVID-19 pandemic based on some early, uncontrolled, and small case series suggesting potential efficacy in the treatment of SARS-CoV-2 infection. Although inÂ vitro data suggest chloroquine and hydroxychloroquine both inhibit coronavirus,<a href="#bib24"><sup>24</sup></a><sup>,</sup><a href="#bib25"><sup>25</sup></a> available clinical data do not suggest any benefit for theÂ treatment of patients critically ill with COVID-19.<a href="#bib26">26</a>, <a href="#bib27">27</a>, <a href="#bib28">28</a>, <a href="#bib29">29</a>, <a href="#bib30">30</a></p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0085">The current data show no significant risk of infection or infectious complications when antimalarials are used for the treatment of immune-mediated disease and therefore suggest low potential for harm in COVID-19 infection. However, data supporting the use of antimalarials for prevention or treatment of COVID-19 are lacking at present, and use of antimalarials outside of a hospital or clinical trial is cautioned against.<a href="#bib31"><sup>31</sup></a></p> </div> </div> <div class="oralsmallmolecules(azathioprine,mycophenolatemofetil,andcyclosporine)" title="sec"> <div class="title" tagx="title" title="title">
Oral small molecules (azathioprine, mycophenolate mofetil, and cyclosporine)</div> <p id="p0090">Using claims data, Schneeweiss etÂ al<a href="#bib32"><sup>32</sup></a> examined the 6-month risk of serious and opportunistic infections in patients with atopic dermatitis. Compared with methotrexate, cyclosporine A had a 58% higher risk of overall infection (adjusted RR, 1.58; 95% CI, 1.17-2.15). In the same study, azathioprine had double the infection risk (RR, 1.78; 95% CI, 0.98-3.25), whereas mycophenolate mofetil tripled the risk (RR, 3.31; 95% CI, 1.94-5.64). A separate study comparing patients with systemic lupus erythematosus newly treated with mycophenolate mofetil or azathioprine found no differences in rates of serious infections.<a href="#bib33"><sup>33</sup></a> Studies that examined the incidence of viral infections found that herpes zoster virus infections are increased with azathioprine<a href="#bib34"><sup>34</sup></a><sup>,</sup><a href="#bib35"><sup>35</sup></a> and that cytomegalovirus infections are increased with mycophenolate mofetil,<a href="#bib36"><sup>36</sup></a> although the latter appears to be limited to patients who have received a transplant.</p> <div class="therapeuticpotentialincovid-19" title="sec"> <div class="title" tagx="title" title="title">
Therapeutic potential in COVID-19</div> <p id="p0095">Some authors have suggested the use of cyclosporine in the treatment of COVID-19<a href="#bib37"><sup>37</sup></a> based on its ability to inhibit coronavirus replication inÂ vitro.<a href="#bib38"><sup>38</sup></a><sup>,</sup><a href="#bib39"><sup>39</sup></a> That said, its clinical efficacy has not been proven, and thereÂ are no ongoing clinical trials in patients with COVID-19.</p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0100">Azathioprine, mycophenolate mofetil, and cyclosporine A increase the risk of infection relative to reference agents such as methotrexate, warranting increased caution and discussion with patients regarding starting or continuing therapy.</p> </div> </div> <div class="apremilast" title="sec"> <div class="title" tagx="title" title="title">
Apremilast</div> <p id="p0105">Long-term safety data from open-label extension studies in psoriasis and psoriatic arthritis do not show an increased risk of serious infections compared with placebo.<a href="#bib40"><sup>40</sup></a><sup>,</sup><a href="#bib41"><sup>41</sup></a> Similarly, URI and nasopharyngitis rates were comparable in the placebo-controlled phases of these studies.</p> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0110">The available data suggest a low risk of infection associated with the use of apremilast and, therefore, low potential for harm in COVID-19 infection.</p> </div> </div> <div class="januskinaseinhibitors" title="sec"> <div class="title" tagx="title" title="title">
Janus kinase inhibitors</div> <p id="p0115">The bulk of the safety data regarding Janus kinase (JAK) inhibitors comes from the use of tofacitinib in rheumatoid arthritis. Analysis of the most recent tofacitinib data from randomized controlled trials and long-term extension studies in rheumatoid arthritis reveals serious infection rates of 2.4 per 100 patient-years,<a href="#bib42"><sup>42</sup></a> comparable to the event rates reported for biologic disease-modifying antirheumatic drugs<a href="#bib43"><sup>43</sup></a><sup>,</sup><a href="#bib44"><sup>44</sup></a> and baricitinib.<a href="#bib45"><sup>45</sup></a> A particular concern with JAK inhibition is the risk of varicella zoster virus reactivation and antiviral immunity. This appears to be a class effect due to impairment of the interferon antiviral response. It has been noted across all indications and occurs at an increased rate with both selective and nonselective JAK inhibitors.<a href="#bib46">46</a>, <a href="#bib47">47</a>, <a href="#bib48">48</a></p> <div class="therapeuticpotentialincovid-19" title="sec"> <div class="title" tagx="title" title="title">
Therapeutic potential in COVID-19</div> <p id="p0120">Ruxolitinib (NCT04362137) and baricitinib (NCT04280705) are currently being evaluated in phase III clinical trials for potential therapeutic effect in patients critically ill with COVID-19. It is suggested that preferential inhibition of JAK1 and JAK2 significantly downregulates the production of interleukin (IL) 6 and interferon-Î³, both of which are implicated in the hyperinflammatory state seen in patients critically ill with COVID-19.<a href="#bib10"><sup>10</sup></a><sup>,</sup><a href="#bib49"><sup>49</sup></a> Moreover, unlike tofacitinib, baricitinib and ruxolitinib have demonstrated antiviral activity via inhibition of receptor-mediated endocytosis of SARS-CoV-2 viral particles.<a href="#bib50"><sup>50</sup></a></p> </div> <div class="additionalconcernsincovid-19" title="sec"> <div class="title" tagx="title" title="title">
Additional concerns in COVID-19</div> <p id="p0125">A high rate of venous thromboembolism (VTE) has been noted in COVID-19, occurring in up to one-third of critically ill patients, despite prophylactic anticoagulation.<a href="#bib51"><sup>51</sup></a><sup>,</sup><a href="#bib52"><sup>52</sup></a> Because JAK inhibitors carry a â€œblack boxÂ warningâ€� of increased VTE risk, there is reasonable concern that their use may increase the likelihood or severity of VTE when used in patients with COVID-19.<a href="#bib53"><sup>53</sup></a></p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0130">The use of JAK inhibitors is associated with an increased risk of serious infection, herpes zoster virus reactivation, and VTE. However, recent studies show potential direct antiviral and anti-inflammatory effects in COVID-19, seemingly unique to ruxolitinib and baricitinib. Taken together, there are insufficient data at this time to fully characterize the risk of harm or benefit in SARS-CoV-2 infection.</p> </div> </div> <div class="anticytokinebiologictherapy" title="sec"> <div class="title" tagx="title" title="title">
Anticytokine biologic therapy</div> <p id="p0135">Data from BIOBADADERM (Spanish Registry ofÂ Adverse Events for Biological Therapy in Dermatological Diseases), a Spanish registry designed to study the safety of systemic therapy in psoriasis, showed an increased risk of overall infection with tumor necrosis factor (TNF) inhibitors compared with ustekinumab and nonbiologic drugs (acitretin, cyclosporine, and methotrexate). Of all TNF inhibitors, infliximab had the highest risk of infection (adjusted riskÂ ratio, 1.71; 95% CI, 1.1-2.65).<a href="#bib54"><sup>54</sup></a> Similarly, data from the large Psoriasis Longitudinal Assessment and Registry (PSOLAR) indicated a higher risk of serious infections with adalimumab and infliximab compared with nonbiologic drugs.<a href="#bib55"><sup>55</sup></a> Conversely, no increased risk of serious infections was noted when ustekinumab and etanercept were compared with nonbiologic drugs.<a href="#bib55"><sup>55</sup></a></p> <p id="p0140">Recently, Murrell etÂ al<a href="#bib56"><sup>56</sup></a> reviewed data from pivotal clinical trials in psoriasis and found that URIs were increased with TNF inhibitors compared with placebo but that URI rates were comparable between placebo and IL-17, IL-12/23, and IL-23 inhibitors. A different group also reviewed the clinical trial data for all 11 biologic therapies approved in psoriasis and found no significant increase in URI or influenza infection rates compared with placebo.<a href="#bib57"><sup>57</sup></a> In contrast, Wan etÂ al<a href="#bib58"><sup>58</sup></a> recently published a meta-estimate of pivotal clinical trials with 3 IL-17 inhibitors and found an increased risk of viral and nonviral URIs compared with placebo (odds ratio [OR], 1.56; 95% CI, 1.04-2.33).</p> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0145">Taken together, these data suggest a low risk of harm with IL-12/23 or IL-23 inhibition. Further data are needed regarding any potential increased risk of viral and nonviral URIs associated with IL-17 inhibition. The data presented indicate higher rates of overall infection and URIs with TNF inhibitors; however, ongoing trials investigating the therapeutic potential of adalimumab in the COVID-19â€"related cytokine storm are still underway, and this precludes any definitive comments relating to the safety of TNF inhibitors in COVID-19.</p> </div> </div> <div class="rituximab" title="sec"> <div class="title" tagx="title" title="title">
Rituximab</div> <p id="p0150">Reactivation of chronic viral infections, such as hepatitis B and cytomegalovirus, is a rare yet well-reported adverse effect of rituximab.<a href="#bib59"><sup>59</sup></a> Other viral illnesses, such as URIs and nasopharyngitis, are frequently reported, but clinical trial data in rheumatoid arthritis suggest similar overall rates of infections when rituximab is compared with methotrexate plus placebo.<a href="#bib60"><sup>60</sup></a><sup>,</sup><a href="#bib61"><sup>61</sup></a> Long-term observational studies also show that this risk remains stable with repeated infusions.<a href="#bib62"><sup>62</sup></a><sup>,</sup><a href="#bib63"><sup>63</sup></a> Data in the dermatologic literature are limited, but a randomized controlled trial in pemphigus vulgaris showed a similar rate of infections in the rituximab plus short-term steroid group compared with the steroid-only group.<a href="#bib64"><sup>64</sup></a> However, it is worth noting that the rituximab group had lower cumulative exposure to prednisone.</p> <p id="p0155">An important consideration is the risk of prolonged hypogammaglobulinemia, especially with repeated courses of rituximab.<a href="#bib65"><sup>65</sup></a> Cases characterized in the literature reveal an increased risk of URIs, pneumonias, and viral infections, including fatal instances of enteroviral meningoencephalitis.<a href="#bib66"><sup>66</sup></a><sup>,</sup><a href="#bib67"><sup>67</sup></a></p> <div class="particularconcernsincovid-19" title="sec"> <div class="title" tagx="title" title="title">
Particular concerns in COVID-19</div> <p id="p0160">There is evidence to suggest that rituximab may blunt protective immune responses to vaccines. Indeed, impaired antibody responses are seen to both influenza and polysaccharide vaccines, with effects lasting up to 6Â months after treatment with rituximab.<a href="#bib68"><sup>68</sup></a><sup>,</sup><a href="#bib69"><sup>69</sup></a></p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0165">The data suggest increased rates of infection and infectious complications associated with the use of rituximab. Together with a long immunologic half-life and prolonged impairment of vaccine immunity, there are significant potential safety concerns, suggesting a need for increased caution during the ongoing COVID-19 pandemic. To minimize harm, evaluation (and potential correction) of rituximab-induced hypogammaglobulinemia may be considered among patients who receive recurrent rituximab dosing.</p> </div> </div> <div class="dupilumab" title="sec"> <div class="title" tagx="title" title="title">
Dupilumab</div> <p id="p0170">A comprehensive evaluation of infection risk with dupilumab was conducted by Eichenfield etÂ al.<a href="#bib70"><sup>70</sup></a> Their analysis pooled data from 7 randomized controlled trials in atopic dermatitis, which showed similar infection rates per 100 patient-years in the treatment and placebo groups. Specifically, the rates of viral URIs and influenza infections were lower in the dupilumab groups compared with placebo. Similarly, an observational study by Schneeweiss etÂ al<a href="#bib32"><sup>32</sup></a> found no increase in the rates of serious bacterial or opportunistic infections with dupilumab compared with methotrexate.</p> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="p0175">Data to date suggest a low risk of infection with the use of dupilumab and a low potential for harm in COVID-19.</p> </div> </div> </div> <div class="datafromthecovid-19pandemic" title="sec"> <div class="title" tagx="title" title="title">
Data from the COVID-19 pandemic</div> <p id="p0180">One large case series and 2 registries have reported a combined total of 721 confirmed or highly suspected cases of COVID-19 in adult and pediatric immune-mediated inflammatory disease populations through May 19, 2020.<a href="#bib71">71</a>, <a href="#bib72">72</a>, <a href="#bib73">73</a> The results are summarized in <a href="#tbl2">Table II</a> .<a href="#bib71">71</a>, <a href="#bib72">72</a>, <a href="#bib73">73</a> Haberman etÂ al<a href="#bib71"><sup>71</sup></a> noted that those requiring hospitalization were more likely to have rheumatoid arthritis, had more comorbidities, were older, and had greater use of methotrexate, hydroxychloroquine, and corticosteroids. They also reported an overall incidence of hospitalization of 16%, which was comparable to the 26% incidence in patients with COVID-19 in the general population in New York.<a href="#bib71"><sup>71</sup></a> They concluded that baseline use of biologics was not associated with worse COVID-19 outcomes. <div class="table-wrap_UNKNOWN" position="float" id="tbl2"><span class="label" tagx="label" title="label">Table II</span> </div></p><p>Summary of large case series and registry data of autoimmune disease patients infected or exposed to SARS-CoV-2</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th rowspan="2">Characteristics<a href="#tbl2fnlowast">âˆ—</a></th> <th colspan="3">Studies <hr /> </th> </tr> <tr> <th>Haberman etÂ al<a href="#bib71"><sup>71</sup></a></th> <th>Gianfrancesco etÂ al<a href="#bib72"><sup>72</sup></a></th> <th>Brenner etÂ al<a href="#bib73"><sup>73</sup></a></th> </tr> </thead> <tbody> <tr> <td>Total number of patients<a href="#tbl2fndagger">â€ </a></td> <td align="center">86</td> <td align="center">110</td> <td align="center">525</td> </tr> <tr> <td>Confirmed cases of COVID-19</td> <td align="center">59 (69)</td> <td align="center">110 (100)</td> <td align="center">525 (100)</td> </tr> <tr> <td>Age, mean y</td> <td align="center">46</td> <td align="center">N/A<a href="#tbl2fnddagger">â€¡</a></td> <td align="center">43</td> </tr> <tr> <td>Female sex</td> <td align="center">49 (57)</td> <td align="center">79 (72)</td> <td align="center">243 (46.3)</td> </tr> <tr> <td>Most common diagnosis</td> <td align="center">PsA: 21 (24)</td> <td align="center">RA: 40 (36)</td> <td align="center">CD: 312 (59.4)</td> </tr> <tr> <td>Other diagnoses</td> <td align="center">RA: 20 (23)</td> <td align="center">PsA: 19 (17)</td> <td align="center">UC: 203 (38.7)</td> </tr> <tr> <td /> <td align="center">CD: 20 (23)</td> <td align="center">SLE: 19 (17)</td> <td align="center">IBD unspecified: 7 (1.3)</td> </tr> <tr> <td /> <td align="center">UC: 17 (20)</td> <td align="center">Other: 17 (15)<a href="#tbl2fnsection">Â§</a></td> <td /> </tr> <tr> <td /> <td align="center">Psoriasis: 14 (16)</td> <td align="center">AS: 7 (6)</td> <td /> </tr> <tr> <td /> <td align="center">AS: 9 (10)</td> <td align="center">Vasculitis: 7 (6)</td> <td /> </tr> <tr> <td /> <td /> <td align="center">SjS: 5 (5)</td> <td /> </tr> <tr> <td>Medications</td> <td /> <td /> <td /> </tr> <tr> <td>Biologic drugs</td> <td align="center">TNFi: 38 (44)</td> <td align="center">Unspecified: 49 (45)</td> <td align="center">TNFi alone: 176 (33.5)</td> </tr> <tr> <td /> <td align="center">IL-17i: 6 (7)</td> <td /> <td align="center">IL-12/23i: 55 (10.5)</td> </tr> <tr> <td /> <td align="center">IL-12/23i: 6 (7)</td> <td /> <td align="center">TNFiÂ +Â DMARD: 52 (9.9)</td> </tr> <tr> <td /> <td align="center">IL-23i: 3 (3)</td> <td /> <td align="center">Î±-Integrin: 50 (9.5)</td> </tr> <tr> <td>JAKi</td> <td align="center">6 (7)</td> <td align="center">5 (5)</td> <td align="center">8 (1.5)</td> </tr> <tr> <td>csDMARD</td> <td align="center">MTX: 17 (20)</td> <td align="center">69 (63)</td> <td align="center">110 (21)</td> </tr> <tr> <td>Hydroxychloroquine</td> <td align="center">8 (9)</td> <td align="center">N/A</td> <td align="center">0</td> </tr> <tr> <td>Hospitalization</td> <td align="center">14 (16)</td> <td align="center">39 (35)</td> <td align="center">161 (31)</td> </tr> <tr> <td>Deaths</td> <td align="center">1 (1)</td> <td align="center">6 (5)</td> <td align="center">16 (3)</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p><i>AS</i>, Ankylosing spondylitis; <i>CD</i>, Crohn's disease; <i>COVID-19</i>, coronavirus disease 2019; <i>csDMARD</i>, conventional synthetic disease-modifying antirheumatic drug; <i>IBD</i>, inflammatory bowel disease; <i>IL</i>, interleukin; <i>JAK</i>, Janus kinase inhibitor; <i>MTX</i>, methotrexate; <i>N/A</i>, not available; <i>PsA</i>, psoriatic arthritis; <i>RA</i>, rheumatoid arthritis; <i>SARS-Cov-2</i>, severe acute respiratory syndrome coronavirus 2; <i>SjS</i>, SjÃ¶gren syndrome; <i>SLE</i>, systemic lupus erythematosus; <i>TNFi</i>, tumor necrosis factor-Î± inhibitor; <i>UC</i>, ulcerative colitis.</p> </div> </div> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">âˆ—</span><p id="ntpara0030">Data are shown as number (%) or as indicated otherwise.</p> </div> </div> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">â€ </span><p id="ntpara0035">Includes both confirmed and highly suspected cases of COVID-19.</p> </div> </div> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">â€¡</span><p id="ntpara0040">20% of patients were aged &amp;gt;65Â years.</p> </div> </div> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">Â§</span><p id="ntpara0045">Other included (all with nÂ <div class="â_UNKNOWN"> </div></p></div> </div>  <p /> <p id="p0185">In the inflammatory bowel disease registry, 16 deaths (3%) were identified, with half occurring in patients aged &amp;gt;70Â years, whereas no deaths were noted in patients aged &amp;lt;30Â years. On multivariate analysis, Brenner etÂ al<a href="#bib73"><sup>73</sup></a> reported a strong association between systemic steroids and the composite outcome of intensive care unit admission, ventilator use, and death (adjusted OR, 6.9; 95% CI, 2.3-20.5). In contrast, no association was seen between TNF inhibitor monotherapy and poor COVID-19 outcomes (adjusted OR, 0.90; 95% CI, 0.37-2.17). Although the authors did not report on the use of IL-12/23 inhibitors, as of May 19, 2020, data from the registry (available for viewing on <a href="http://covidibd.org">covidibd.org</a>) revealed 1170 cases, with 9% (100 of 1170) of patients having poor outcomes. Among subgroups, 23% (23 of 98) of steroid users had poor outcomes compared with only 2% (8 of 337) of patients on TNF inhibitor monotherapy and 3% (3 of 112) of patients on IL-12/23 inhibitors.</p> <p id="p0190">With regards to infection risk, a case-control study by Damiani etÂ al<a href="#bib74"><sup>74</sup></a> evaluated 1193 patients with psoriasis and identified only 16 cases of COVID-19 from February 21 to April 9, 2020. Compared with the general population of Lombardy, patients on biologics had a higher risk of testing positive for COVID-19 (OR, 3.43; 95% CI, 2.25-5.73) and hospitalization (OR, 3.59; 95% CI, 1.49-8.63).</p> <div class="sec" title="sec"> <div class="conclusion" title="sec"> <div class="title" tagx="title" title="title">
Conclusion</div> <p id="p0195">Most of the patients on systemic immunosuppressive or immunomodulatory therapy included in these studies did not require hospitalization, and death remained a rare outcome. However, systemic corticosteroid use in this patient population appeared to increase the risk of poor outcomes in COVID-19.</p> </div> </div> </div> <div class="discussionandrecommendations" title="sec"> <div class="title" tagx="title" title="title">
Discussion and recommendations</div> <p id="p0200">We believe a patient-centered approach, with shared decision making informed by the data presented here, will help mitigate risk to our patients. Factors to consider are summarized in <a href="#tbl1">Table I</a>. Our interpretation of the literature based on the highest quality of evidence available to date is found in <a href="#tbl3">Table III</a> . The overarching principles are that immunosuppressive and immunomodulatory therapy can be safely initiated or continued in most patients. Physicians should alter and optimize regimens in favor of lower-risk options where possible, and as outlined more specifically in <a href="#tbl3">Table III</a> and <a href="#fig1">Fig 1</a> . <div class="table-wrap_UNKNOWN" position="float" id="tbl3"><span class="label" tagx="label" title="label">Table III</span> </div></p><p>Guidance statements for management of immunosuppression during the coronavirus disease 2019 (<i>COVID-19</i>) pandemic<a href="#tbl3fnlowast">âˆ—</a></p>  <table frame="hsides" rules="groups"> <tbody> <tr> <td>Patients well-controlled on maintenance therapy</td> <td>We suggest continuing immunosuppressive/immunomodulatory therapy at the lowest necessary effective dose, because immunosuppression alone does not appear to predict poor COVID-19 outcomes.<br /><br />We do note the following exceptions: <ul> <li><span class="label" tagx="label" title="label">a.</span><p id="p0240">Long-term systemic steroids should be tapered to daily doses &amp;lt;10Â mg prednisone equivalent, if safe to do so.</p> </li> <li><span class="label" tagx="label" title="label">b.</span><p id="p0245">Patients on recurrent rituximab dosing may benefit from immunoglobulin level testing. If hypogammaglobulinemia exists, consider altering/delaying dose or initiating immunoglobulin therapy, or both.</p> </li> </ul> </td> </tr> <tr> <td>Patients requiring initiation of treatment</td> <td>We suggest the following: <ul> <li><span class="label" tagx="label" title="label">a.</span><p id="p0250">On the basis of disease severity and baseline risk, consider favoring low-risk immunomodulatory agents (eg, apremilast, hydroxychloroquine, methotrexate) over immunosuppressive agents with a higher known or suspected risk of infection (see <a href="#tbl2">Table II</a>).</p> </li> <li><span class="label" tagx="label" title="label">b.</span><p id="p0255">When medically appropriate, opt for short courses of low to moderate doses of systemic corticosteroids over high-dose regimens (eg, &amp;lt;20Â mg prednisone equivalent daily for &amp;lt;2Â weeks); if needed for maintenance therapy, consider doses &amp;lt;10Â mg daily.</p> </li> <li><span class="label" tagx="label" title="label">c.</span><p id="p0260">When possible, avoid starting rituximab, due to its prolonged B-cellâ€"depleting effects, if equally efficacious alternative therapies are available; exceptions include mucous membrane blistering disorders.</p> </li> <li><span class="label" tagx="label" title="label">d.</span><p id="p0265">If possible, use alternatives to cyclosporine and other agents requiring intensive toxicity/safety monitoring.</p> </li> </ul> </td> </tr> <tr> <td>Patients with active COVID-19 infection, including COVID-19<sup>+</sup> testing (even in the absence of symptoms)</td> <td>Although the potential benefit of immunosuppression is being studied in the context of cytokine storm, we suggest that, if possible, immunosuppressive therapy be held in patients testing positive for COVID-19, even if asymptomatic, with the concern being the complication of bacterial infections and pneumonia. Many systemic immunosuppressive drugs have long half-lives, and temporary cessation of therapy is unlikely to result in disease flare. Individual discussions may be considered for severe flares with potentially organ-threatening manifestations. Treatment can resume after recovery (refer to Centers for Disease Control and Prevention or local health authority for recovery criteria).<br /><br />Exceptions to the above include: <ul> <li><span class="label" tagx="label" title="label">a.</span><p id="p0270">Systemic steroids may be tapered but not stopped abruptly. Providers should follow recommendations for corticosteroid stress doses in critically ill patients.</p> </li> <li><span class="label" tagx="label" title="label">b.</span><p id="p0275">Drugs with minimal immunosuppressive potential (e.g., apremilast, antimalarials) may be continued after thorough patient assessment (refer to <a href="#tbl1">Table I</a>).</p> </li> </ul> </td> </tr> <tr> <td>Patients with active immune-mediated skin disease</td> <td> <ul> <li><span class="label" tagx="label" title="label">a.</span><p id="p0280">When possible, maximize/optimize nonimmunosuppressive therapy, such as topical steroids, immunomodulatory agents (eg, apremilast, antimalarials, and retinoids), and anti-inflammatory medications (eg, tetracycline or macrolide class antibiotics).</p> </li> <li><span class="label" tagx="label" title="label">b.</span><p id="p0285">High-dose systemic corticosteroids should be avoided where possible, and taper plans should be kept to the minimum necessary dose and duration.</p> </li> </ul> </td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">âˆ—</span><p id="ntpara0050">With limited COVID-specific safety data available on any given treatment, it is challenging to produce firm recommendations on the safety of immunosuppression in the context of the current pandemic. Notably, our guidance statements are based on expert opinion and interpretation of safety data deemed most relevant rather than on formal guidelines derived from high-quality comparative studies. Limitations include the heterogeneity of the safety data encompassing various autoimmune conditions and the limited reports available on the status of immunosuppressed patients affected by COVID-19. The applicability of the information and recommendations provided here are limited by the rapidly evolving nature of the COVID-19 pandemic, in addition to patient-specific and local health care constraints. Decisions should ultimately be individualized to a specific scenario, and reflective of shared-decision making between provider and patient.</p> </div> </div>  <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">FigÂ 1</span></a></div>   <p>Drug safety recommendations in the context of the coronavirus disease 2019 (COVID-19) pandemic. <i>CMV</i>, Cytomegalovirus; <i>DVT</i>, deep venous thrombosis; <i>HZV</i>, herpes zoster virus; <i>IL</i>, interleukin; <i>PE</i>, pulmonary embolus; <i>URI</i>, upper respiratory infection.</p>   </div> <p /> <p id="p0205">Further data regarding the safety of these agents are needed and constitute a key unmet need for our patients.</p> </div> </div> <div class="back" title="back"> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="bib1" /><span class="label" tagx="label" title="label">1</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wakkee</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Vries</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van den Haak</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nijsten</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort</span><span class="source" tagx="source" title="source">J Am Acad Dermatol</span><span class="volume" tagx="volume" title="volume">65</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2011</span><span class="fpage" tagx="fpage" title="fpage">1135</span><span class="lpage" tagx="lpage" title="lpage">1144</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21664719">21664719</a></span></span></li> <li tag="ref"><a name="bib2" /><span class="label" tagx="label" title="label">2</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Herrinton</span><span class="given-names" tagx="given-names" title="given-names">L.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Goldfien</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Michaels</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tran</span><span class="given-names" tagx="given-names" title="given-names">T.N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Risk of serious infection for patients with systemic lupus erythematosus starting glucocorticoids with or without antimalarials</span><span class="source" tagx="source" title="source">J Rheumatol</span><span class="volume" tagx="volume" title="volume">43</span><span class="issue" tagx="issue" title="issue">8</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">1503</span><span class="lpage" tagx="lpage" title="lpage">1509</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27370880">27370880</a></span></span></li> <li tag="ref"><a name="bib3" /><span class="label" tagx="label" title="label">3</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Perez-Chada</span><span class="given-names" tagx="given-names" title="given-names">L.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Merola</span><span class="given-names" tagx="given-names" title="given-names">J.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Comorbidities associated with psoriatic arthritis: review and update</span><span class="source" tagx="source" title="source">Clin Immunol</span><span class="volume" tagx="volume" title="volume">214</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">108397</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32229290">32229290</a></span></span></li> <li tag="ref"><a name="bib4" /><span class="label" tagx="label" title="label">4</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hu</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hu</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</span><span class="source" tagx="source" title="source">JAMA</span><span class="volume" tagx="volume" title="volume">323</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1061</span><span class="lpage" tagx="lpage" title="lpage">1069</span></span></li> <li tag="ref"><a name="bib5" /><span class="label" tagx="label" title="label">5</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hui</span><span class="given-names" tagx="given-names" title="given-names">D.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Azhar</span><span class="given-names" tagx="given-names" title="given-names">E.I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">Y.-J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Memish</span><span class="given-names" tagx="given-names" title="given-names">Z.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oh</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zumla</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission</span><span class="source" tagx="source" title="source">Lancet Infect Dis</span><span class="volume" tagx="volume" title="volume">18</span><span class="issue" tagx="issue" title="issue">8</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">e217</span><span class="lpage" tagx="lpage" title="lpage">e227</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29680581">29680581</a></span></span></li> <li tag="ref"><a name="bib6" /><span class="label" tagx="label" title="label">6</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dâ€™Antiga</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Coronaviruses and immunosuppressed patients: the facts during the third epidemic</span><span class="source" tagx="source" title="source">Liver Transpl</span><span class="volume" tagx="volume" title="volume">26</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">832</span><span class="lpage" tagx="lpage" title="lpage">834</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32196933">32196933</a></span></span></li> <li tag="ref"><a name="bib7" /><span class="label" tagx="label" title="label">7</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lam</span><span class="given-names" tagx="given-names" title="given-names">M.-F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ooi</span><span class="given-names" tagx="given-names" title="given-names">G.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lam</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">An indolent case of severe acute respiratory syndrome</span><span class="source" tagx="source" title="source">Am J Respir Crit Care Med</span><span class="volume" tagx="volume" title="volume">169</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2004</span><span class="fpage" tagx="fpage" title="fpage">125</span><span class="lpage" tagx="lpage" title="lpage">128</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14695107">14695107</a></span></span></li> <li tag="ref"><a name="bib8" /><span class="label" tagx="label" title="label">8</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">S.-H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ko</span><span class="given-names" tagx="given-names" title="given-names">J.-H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">G.E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Atypical presentations of MERS-CoV infection in immunocompromised hosts</span><span class="source" tagx="source" title="source">J Infect Chemother</span><span class="volume" tagx="volume" title="volume">23</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">769</span><span class="lpage" tagx="lpage" title="lpage">773</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28545936">28545936</a></span></span></li> <li tag="ref"><a name="bib9" /><span class="label" tagx="label" title="label">9</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Prescott</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Falzarano</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Wit</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pathogenicity and viral shedding of MERS-CoV in immunocompromised rhesus macaques</span><span class="source" tagx="source" title="source">Front Immunol</span><span class="volume" tagx="volume" title="volume">9</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">205</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29483914">29483914</a></span></span></li> <li tag="ref"><a name="bib10" /><span class="label" tagx="label" title="label">10</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Merad</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Martin</span><span class="given-names" tagx="given-names" title="given-names">J.C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages</span><span class="source" tagx="source" title="source">Nat Rev Immunol</span><span class="volume" tagx="volume" title="volume">20</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">355</span><span class="lpage" tagx="lpage" title="lpage">362</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32376901">32376901</a></span></span></li> <li tag="ref"><a name="bib11" /><span class="label" tagx="label" title="label">11</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stuck</span><span class="given-names" tagx="given-names" title="given-names">A.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Minder</span><span class="given-names" tagx="given-names" title="given-names">C.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Frey</span><span class="given-names" tagx="given-names" title="given-names">F.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Risk of infectious complications in patients taking glucocorticosteroids</span><span class="source" tagx="source" title="source">Rev Infect Dis</span><span class="volume" tagx="volume" title="volume">11</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">1989</span><span class="fpage" tagx="fpage" title="fpage">954</span><span class="lpage" tagx="lpage" title="lpage">963</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2690289">2690289</a></span></span></li> <li tag="ref"><a name="bib12" /><span class="label" tagx="label" title="label">12</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Migita</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sasaki</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ishizuka</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease</span><span class="source" tagx="source" title="source">Medicine (Baltimore)</span><span class="volume" tagx="volume" title="volume">92</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">285</span><span class="lpage" tagx="lpage" title="lpage">293</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23982055">23982055</a></span></span></li> <li tag="ref"><a name="bib13" /><span class="label" tagx="label" title="label">13</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Greenberg</span><span class="given-names" tagx="given-names" title="given-names">J.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reed</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kremer</span><span class="given-names" tagx="given-names" title="given-names">J.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry</span><span class="source" tagx="source" title="source">Ann Rheum Dis</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2010</span><span class="fpage" tagx="fpage" title="fpage">380</span><span class="lpage" tagx="lpage" title="lpage">386</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19359261">19359261</a></span></span></li> <li tag="ref"><a name="bib14" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. Published online January 1, 2020:2020.06.22.20137273. <span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.06.22.20137273">10.1101/2020.06.22.20137273</a></span>.</span></li> <li tag="ref"><a name="bib15" /><span class="label" tagx="label" title="label">15</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Allen Chan</span><span class="given-names" tagx="given-names" title="given-names">K.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hui</span><span class="given-names" tagx="given-names" title="given-names">D.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients</span><span class="source" tagx="source" title="source">J Clin Virol</span><span class="volume" tagx="volume" title="volume">31</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">2004</span><span class="fpage" tagx="fpage" title="fpage">304</span><span class="lpage" tagx="lpage" title="lpage">309</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15494274">15494274</a></span></span></li> <li tag="ref"><a name="bib16" /><span class="label" tagx="label" title="label">16</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hui</span><span class="given-names" tagx="given-names" title="given-names">D.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Systemic corticosteroid therapy may delay viral clearance in patients with Middle East respiratory syndrome coronavirus infection</span><span class="source" tagx="source" title="source">Am J Respir Crit Care Med</span><span class="volume" tagx="volume" title="volume">197</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">700</span><span class="lpage" tagx="lpage" title="lpage">701</span></span></li> <li tag="ref"><a name="bib17" /><span class="label" tagx="label" title="label">17</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arabi</span><span class="given-names" tagx="given-names" title="given-names">Y.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mandourah</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Hameed</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome</span><span class="source" tagx="source" title="source">Am J Respir Crit Care Med</span><span class="volume" tagx="volume" title="volume">197</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">757</span><span class="lpage" tagx="lpage" title="lpage">767</span></span></li> <li tag="ref"><a name="bib18" /><span class="label" tagx="label" title="label">18</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lansbury</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rodrigo</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Leonardi-Bee</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nguyen-Van-Tam</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lim</span><span class="given-names" tagx="given-names" title="given-names">W.S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Corticosteroids as adjunctive therapy in the treatment of influenza</span><span class="source" tagx="source" title="source">Cochrane Database Syst Rev</span><span class="volume" tagx="volume" title="volume">2</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">CD010406</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30798570">30798570</a></span></span></li> <li tag="ref"><a name="bib19" /><span class="label" tagx="label" title="label">19</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ni</span><span class="given-names" tagx="given-names" title="given-names">Y.-N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liang</span><span class="given-names" tagx="given-names" title="given-names">B.-M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liang</span><span class="given-names" tagx="given-names" title="given-names">Z.-A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis</span><span class="source" tagx="source" title="source">Crit Care</span><span class="volume" tagx="volume" title="volume">23</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">99</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30917856">30917856</a></span></span></li> <li tag="ref"><a name="bib20" /><span class="label" tagx="label" title="label">20</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Conway</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carey</span><span class="given-names" tagx="given-names" title="given-names">J.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis</span><span class="source" tagx="source" title="source">J Clin Med</span><span class="volume" tagx="volume" title="volume">8</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2018</span><span class="fpage" tagx="fpage" title="fpage">15</span></span></li> <li tag="ref"><a name="bib21" /><span class="label" tagx="label" title="label">21</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Solomon</span><span class="given-names" tagx="given-names" title="given-names">D.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Glynn</span><span class="given-names" tagx="given-names" title="given-names">R.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karlson</span><span class="given-names" tagx="given-names" title="given-names">E.W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Adverse effects of low-dose methotrexate: a randomized trial</span><span class="source" tagx="source" title="source">Ann Intern Med</span><span class="volume" tagx="volume" title="volume">172</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">369</span><span class="lpage" tagx="lpage" title="lpage">380</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32066146">32066146</a></span></span></li> <li tag="ref"><a name="bib22" /><span class="label" tagx="label" title="label">22</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ruiz-Irastorza</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ramos-Casals</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brito-Zeron</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khamashta</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review</span><span class="source" tagx="source" title="source">Ann Rheum Dis</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">01</span><span class="year" tagx="year" title="year">2010</span><span class="fpage" tagx="fpage" title="fpage">20</span><span class="lpage" tagx="lpage" title="lpage">28</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19103632">19103632</a></span></span></li> <li tag="ref"><a name="bib23" /><span class="label" tagx="label" title="label">23</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bernatsky</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hudson</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suissa</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis</span><span class="source" tagx="source" title="source">Rheumatology (Oxford)</span><span class="volume" tagx="volume" title="volume">46</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">1157</span><span class="lpage" tagx="lpage" title="lpage">1160</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17478469">17478469</a></span></span></li> <li tag="ref"><a name="bib24" /><span class="label" tagx="label" title="label">24</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yao</span><span class="given-names" tagx="given-names" title="given-names">X.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ye</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">InÂ vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [e-pub ahead of print]</span><span class="source" tagx="source" title="source">Clin Infect Dis</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/cid/ciaa237">10.1093/cid/ciaa237</a></span></span></li> <li tag="ref"><a name="bib25" /><span class="label" tagx="label" title="label">25</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Keyaerts</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vijgen</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maes</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Neyts</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ranst</span><span class="given-names" tagx="given-names" title="given-names">M.V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">InÂ vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</span><span class="source" tagx="source" title="source">Biochem Biophys Res Commun</span><span class="volume" tagx="volume" title="volume">323</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2004</span><span class="fpage" tagx="fpage" title="fpage">264</span><span class="lpage" tagx="lpage" title="lpage">268</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15351731">15351731</a></span></span></li> <li tag="ref"><a name="bib26" /><span class="label" tagx="label" title="label">26</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pastick</span><span class="given-names" tagx="given-names" title="given-names">K.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Okafor</span><span class="given-names" tagx="given-names" title="given-names">E.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)</span><span class="source" tagx="source" title="source">Open Forum Infect Dis</span><span class="volume" tagx="volume" title="volume">7</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">ofaa130</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32363212">32363212</a></span></span></li> <li tag="ref"><a name="bib27" /><span class="label" tagx="label" title="label">27</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mahevas</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tran</span><span class="given-names" tagx="given-names" title="given-names">V.-T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roumier</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial [preprint]</span><span class="source" tagx="source" title="source">medRxiv</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.04.10.20060699">10.1101/2020.04.10.20060699</a></span></span></li> <li tag="ref"><a name="bib28" /><span class="label" tagx="label" title="label">28</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Geleris</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Platt</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Observational study of hydroxychloroquine in hospitalized patients with Covid-19</span><span class="source" tagx="source" title="source">N Engl J Med</span><span class="volume" tagx="volume" title="volume">382</span><span class="issue" tagx="issue" title="issue">25</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">2411</span><span class="lpage" tagx="lpage" title="lpage">2418</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32379955">32379955</a></span></span></li> <li tag="ref"><a name="bib29" /><span class="label" tagx="label" title="label">29</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Magagnoli</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Narendran</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pereira</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 [preprint]</span><span class="source" tagx="source" title="source">medRxiv</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.04.16.20065920">10.1101/2020.04.16.20065920</a></span></span></li> <li tag="ref"><a name="bib30" /><span class="label" tagx="label" title="label">30</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tang</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">Z.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Han</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Hydroxychloroquine in patients mainly with mild to moderate coronavirus disease 2019: an open-label, randomized, controlled trial</span><span class="source" tagx="source" title="source">BMJ</span><span class="volume" tagx="volume" title="volume">369</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">m1849</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32409561">32409561</a></span></span></li> <li tag="ref"><a name="bib31" /><span class="label" tagx="label" title="label">31</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">US Food and Drug Administration</span></span></span><span class="mixed-article-title" title="mixed-article-title">FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems: does not affect FDA-approved uses for malaria, lupus, and rheumatoid arthritis</span><span class="comment">Available at:</span><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or">https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or</a><span class="year" tagx="year" title="year">2020</span></span></li> <li tag="ref"><a name="bib32" /><span class="label" tagx="label" title="label">32</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schneeweiss</span><span class="given-names" tagx="given-names" title="given-names">M.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Perez-Chada</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Merola</span><span class="given-names" tagx="given-names" title="given-names">J.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Comparative safety of systemic immuno-modulatory medications in adults with atopic dermatitis [e-pub ahead of print]</span><span class="source" tagx="source" title="source">J Am Acad Dermatol</span><span class="year" tagx="year" title="year">2019</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jaad.2019.05.073">10.1016/j.jaad.2019.05.073</a></span></span></li> <li tag="ref"><a name="bib33" /><span class="label" tagx="label" title="label">33</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Feldman</span><span class="given-names" tagx="given-names" title="given-names">C.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marty</span><span class="given-names" tagx="given-names" title="given-names">F.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winkelmayer</span><span class="given-names" tagx="given-names" title="given-names">W.C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Comparative rates of serious infections among patients with systemic lupus erythematosus receiving immunosuppressive medications</span><span class="source" tagx="source" title="source">Arthritis Rheumatol</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">387</span><span class="lpage" tagx="lpage" title="lpage">397</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27589220">27589220</a></span></span></li> <li tag="ref"><a name="bib34" /><span class="label" tagx="label" title="label">34</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wisniewski</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kirchgesner</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Seksik</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines</span><span class="source" tagx="source" title="source">United European Gastroenterol J</span><span class="volume" tagx="volume" title="volume">8</span><span class="issue" tagx="issue" title="issue">3</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">303</span><span class="lpage" tagx="lpage" title="lpage">313</span></span></li> <li tag="ref"><a name="bib35" /><span class="label" tagx="label" title="label">35</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wolfe</span><span class="given-names" tagx="given-names" title="given-names">F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Michaud</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chakravarty</span><span class="given-names" tagx="given-names" title="given-names">E.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders</span><span class="source" tagx="source" title="source">Rheumatology (Oxford)</span><span class="volume" tagx="volume" title="volume">45</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2006</span><span class="fpage" tagx="fpage" title="fpage">1370</span><span class="lpage" tagx="lpage" title="lpage">1375</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17003175">17003175</a></span></span></li> <li tag="ref"><a name="bib36" /><span class="label" tagx="label" title="label">36</span><span class="element-citation'"><span class="person-group'"><span class="collab'">collab: The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group</span></span><span class="mixed-article-title" title="mixed-article-title">A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation</span><span class="source" tagx="source" title="source">Transplantation</span><span class="volume" tagx="volume" title="volume">61</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">1996</span><span class="fpage" tagx="fpage" title="fpage">1029</span><span class="lpage" tagx="lpage" title="lpage">1037</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8623181">8623181</a></span></span></li> <li tag="ref"><a name="bib37" /><span class="label" tagx="label" title="label">37</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cour</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ovize</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Argaud</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?</span><span class="source" tagx="source" title="source">Crit Care</span><span class="volume" tagx="volume" title="volume">24</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">276</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32487139">32487139</a></span></span></li> <li tag="ref"><a name="bib38" /><span class="label" tagx="label" title="label">38</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Wilde</span><span class="given-names" tagx="given-names" title="given-names">A.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zevenhoven-Dobbe</span><span class="given-names" tagx="given-names" title="given-names">J.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van der Meer</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cyclosporin A inhibits the replication of diverse coronaviruses</span><span class="source" tagx="source" title="source">J Gen Virol</span><span class="volume" tagx="volume" title="volume">92</span><span class="issue" tagx="issue" title="issue">Pt 11</span><span class="year" tagx="year" title="year">2011</span><span class="fpage" tagx="fpage" title="fpage">2542</span><span class="lpage" tagx="lpage" title="lpage">2548</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21752960">21752960</a></span></span></li> <li tag="ref"><a name="bib39" /><span class="label" tagx="label" title="label">39</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tanaka</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sato</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sasaki</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Suppression of coronavirus replication by cyclophilin inhibitors</span><span class="source" tagx="source" title="source">Viruses</span><span class="volume" tagx="volume" title="volume">5</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">1250</span><span class="lpage" tagx="lpage" title="lpage">1260</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23698397">23698397</a></span></span></li> <li tag="ref"><a name="bib40" /><span class="label" tagx="label" title="label">40</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Crowley</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">ThaÃ§i</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Joly</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for â‰¥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)</span><span class="source" tagx="source" title="source">J Am Acad Dermatol</span><span class="volume" tagx="volume" title="volume">77</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">310</span><span class="lpage" tagx="lpage" title="lpage">317.e1</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28416342">28416342</a></span></span></li> <li tag="ref"><a name="bib41" /><span class="label" tagx="label" title="label">41</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kavanaugh</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gladman</span><span class="given-names" tagx="given-names" title="given-names">D.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Edwards</span><span class="given-names" tagx="given-names" title="given-names">C.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1â€"3 pooled analysis</span><span class="source" tagx="source" title="source">Arthritis Res Ther</span><span class="volume" tagx="volume" title="volume">21</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">118</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31077258">31077258</a></span></span></li> <li tag="ref"><a name="bib42" /><span class="label" tagx="label" title="label">42</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wollenhaupt</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">E.-B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Curtis</span><span class="given-names" tagx="given-names" title="given-names">J.R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety and efficacy of tofacitinib for up to 9.5â€‰years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study</span><span class="source" tagx="source" title="source">Arthritis Res Ther</span><span class="volume" tagx="volume" title="volume">21</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">89</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30953540">30953540</a></span></span></li> <li tag="ref"><a name="bib43" /><span class="label" tagx="label" title="label">43</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vieira</span><span class="given-names" tagx="given-names" title="given-names">M.-C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zwillich</span><span class="given-names" tagx="given-names" title="given-names">S.H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jansen</span><span class="given-names" tagx="given-names" title="given-names">J.P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smiechowski</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Spurden</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wallenstein</span><span class="given-names" tagx="given-names" title="given-names">G.V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis</span><span class="source" tagx="source" title="source">Clin Ther</span><span class="volume" tagx="volume" title="volume">38</span><span class="issue" tagx="issue" title="issue">12</span><span class="year" tagx="year" title="year">2016</span><span class="fpage" tagx="fpage" title="fpage">2628</span><span class="lpage" tagx="lpage" title="lpage">2641.e5</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27889300">27889300</a></span></span></li> <li tag="ref"><a name="bib44" /><span class="label" tagx="label" title="label">44</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Strand</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahadieh</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DeMasi</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">THU0211 Meta-analysis of serious infections with baricitinib, tofacitinib and biologic DMARDs in rheumatoid arthritis [abstract]</span><span class="source" tagx="source" title="source">Ann Rheum Dis</span><span class="volume" tagx="volume" title="volume">76</span><span class="issue" tagx="issue" title="issue">Suppl 2</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">284</span></span></li> <li tag="ref"><a name="bib45" /><span class="label" tagx="label" title="label">45</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smolen</span><span class="given-names" tagx="given-names" title="given-names">J.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Genovese</span><span class="given-names" tagx="given-names" title="given-names">M.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Takeuchi</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment</span><span class="source" tagx="source" title="source">J Rheumatol</span><span class="volume" tagx="volume" title="volume">46</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">7</span><span class="lpage" tagx="lpage" title="lpage">18</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30219772">30219772</a></span></span></li> <li tag="ref"><a name="bib46" /><span class="label" tagx="label" title="label">46</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winthrop</span><span class="given-names" tagx="given-names" title="given-names">K.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Curtis</span><span class="given-names" tagx="given-names" title="given-names">J.R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lindsey</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy</span><span class="source" tagx="source" title="source">Arthritis Rheumatol</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">10</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">1960</span><span class="lpage" tagx="lpage" title="lpage">1968</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28845604">28845604</a></span></span></li> <li tag="ref"><a name="bib47" /><span class="label" tagx="label" title="label">47</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olivera</span><span class="given-names" tagx="given-names" title="given-names">P.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lasa</span><span class="given-names" tagx="given-names" title="given-names">J.S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bonovas</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Danese</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peyrin-Biroulet</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis</span><span class="source" tagx="source" title="source">Gastroenterology</span><span class="volume" tagx="volume" title="volume">158</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1554</span><span class="lpage" tagx="lpage" title="lpage">1573.e12</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31926171">31926171</a></span></span></li> <li tag="ref"><a name="bib48" /><span class="label" tagx="label" title="label">48</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winthrop</span><span class="given-names" tagx="given-names" title="given-names">K.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lebwohl</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cohen</span><span class="given-names" tagx="given-names" title="given-names">A.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Herpes zoster in psoriasis patients treated with tofacitinib</span><span class="source" tagx="source" title="source">J Am Acad Dermatol</span><span class="volume" tagx="volume" title="volume">77</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">302</span><span class="lpage" tagx="lpage" title="lpage">309</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28711084">28711084</a></span></span></li> <li tag="ref"><a name="bib49" /><span class="label" tagx="label" title="label">49</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">McGonagle</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sharif</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">O'Regan</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bridgewood</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease</span><span class="source" tagx="source" title="source">Autoimmun Rev</span><span class="volume" tagx="volume" title="volume">19</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">102537</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32251717">32251717</a></span></span></li> <li tag="ref"><a name="bib50" /><span class="label" tagx="label" title="label">50</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stebbing</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Phelan</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Griffin</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span></span><span class="mixed-article-title" title="mixed-article-title">COVID-19: combining antiviral and anti-inflammatory treatments</span><span class="source" tagx="source" title="source">Lancet Infect Dis</span><span class="volume" tagx="volume" title="volume">20</span><span class="issue" tagx="issue" title="issue">4</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">400</span><span class="lpage" tagx="lpage" title="lpage">402</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32113509">32113509</a></span></span></li> <li tag="ref"><a name="bib51" /><span class="label" tagx="label" title="label">51</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wichmann</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sperhake</span><span class="given-names" tagx="given-names" title="given-names">J.-P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">LÃ¼tgehetmann</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study [e-pub ahead of print]</span><span class="source" tagx="source" title="source">Ann Intern Med</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.7326/M20-2003">10.7326/M20-2003</a></span></span></li> <li tag="ref"><a name="bib52" /><span class="label" tagx="label" title="label">52</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Klok</span><span class="given-names" tagx="given-names" title="given-names">F.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kruip</span><span class="given-names" tagx="given-names" title="given-names">M.J.H.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van der Meer</span><span class="given-names" tagx="given-names" title="given-names">N.J.M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Incidence of thrombotic complications in critically ill ICU patients with COVID-19</span><span class="source" tagx="source" title="source">Thromb Res</span><span class="volume" tagx="volume" title="volume">191</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">145</span><span class="lpage" tagx="lpage" title="lpage">147</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32291094">32291094</a></span></span></li> <li tag="ref"><a name="bib53" /><span class="label" tagx="label" title="label">53</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nash</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews</span><span class="source" tagx="source" title="source">Ann Rheum Dis</span><span class="volume" tagx="volume" title="volume">79</span><span class="issue" tagx="issue" title="issue">6</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">679</span><span class="lpage" tagx="lpage" title="lpage">680</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32033940">32033940</a></span></span></li> <li tag="ref"><a name="bib54" /><span class="label" tagx="label" title="label">54</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">DÃ¡vila-Seijo</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dauden</span><span class="given-names" tagx="given-names" title="given-names">E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Descalzo</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM Registry</span><span class="source" tagx="source" title="source">J Investig Dermatol</span><span class="volume" tagx="volume" title="volume">137</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">313</span><span class="lpage" tagx="lpage" title="lpage">321</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27677836">27677836</a></span></span></li> <li tag="ref"><a name="bib55" /><span class="label" tagx="label" title="label">55</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kalb</span><span class="given-names" tagx="given-names" title="given-names">R.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fiorentino</span><span class="given-names" tagx="given-names" title="given-names">D.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lebwohl</span><span class="given-names" tagx="given-names" title="given-names">M.G.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)</span><span class="source" tagx="source" title="source">JAMA Dermatol</span><span class="volume" tagx="volume" title="volume">151</span><span class="issue" tagx="issue" title="issue">9</span><span class="year" tagx="year" title="year">2015</span><span class="fpage" tagx="fpage" title="fpage">961</span><span class="lpage" tagx="lpage" title="lpage">969</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25970800">25970800</a></span></span></li> <li tag="ref"><a name="bib56" /><span class="label" tagx="label" title="label">56</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lebwohl</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rivera-Oyola</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Murrell</span><span class="given-names" tagx="given-names" title="given-names">D.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Should biologics for psoriasis be interrupted in the era of COVID-19?</span><span class="source" tagx="source" title="source">J Am Acad Dermatol</span><span class="volume" tagx="volume" title="volume">82</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">1217</span><span class="lpage" tagx="lpage" title="lpage">1218</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32199889">32199889</a></span></span></li> <li tag="ref"><a name="bib57" /><span class="label" tagx="label" title="label">57</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brownstone</span><span class="given-names" tagx="given-names" title="given-names">N.D.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thibodeaux</span><span class="given-names" tagx="given-names" title="given-names">Q.G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reddy</span><span class="given-names" tagx="given-names" title="given-names">V.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: infection risk and patient counseling in uncertain times</span><span class="source" tagx="source" title="source">Dermatol Ther (Heidelb)</span><span class="volume" tagx="volume" title="volume">10</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">339</span><span class="lpage" tagx="lpage" title="lpage">349</span></span></li> <li tag="ref"><a name="bib58" /><span class="label" tagx="label" title="label">58</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17â€"pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic [e-pub ahead of print]. <i>J Am Acad Dermatol.</i> 2020. <span class="pub-id"><a href="https://dx.doi.org/10.1016/j.jaad.2020.05.035">10.1016/j.jaad.2020.05.035</a></span>. Accessed May 19, 2020.</span></li> <li tag="ref"><a name="bib59" /><span class="label" tagx="label" title="label">59</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aksoy</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Harputluoglu</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kilickap</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rituximab-related viral infections in lymphoma patients</span><span class="source" tagx="source" title="source">Leuk Lymphoma</span><span class="volume" tagx="volume" title="volume">48</span><span class="issue" tagx="issue" title="issue">7</span><span class="year" tagx="year" title="year">2007</span><span class="fpage" tagx="fpage" title="fpage">1307</span><span class="lpage" tagx="lpage" title="lpage">1312</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17613758">17613758</a></span></span></li> <li tag="ref"><a name="bib60" /><span class="label" tagx="label" title="label">60</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Emery</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Deodhar</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rigby</span><span class="given-names" tagx="given-names" title="given-names">W.F.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naÃ¯ve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))</span><span class="source" tagx="source" title="source">Ann Rheum Dis</span><span class="volume" tagx="volume" title="volume">69</span><span class="issue" tagx="issue" title="issue">9</span><span class="year" tagx="year" title="year">2010</span><span class="fpage" tagx="fpage" title="fpage">1629</span><span class="lpage" tagx="lpage" title="lpage">1635</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20488885">20488885</a></span></span></li> <li tag="ref"><a name="bib61" /><span class="label" tagx="label" title="label">61</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mease</span><span class="given-names" tagx="given-names" title="given-names">P.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cohen</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gaylis</span><span class="given-names" tagx="given-names" title="given-names">N.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE Trial</span><span class="source" tagx="source" title="source">J Rheumatol</span><span class="volume" tagx="volume" title="volume">37</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2010</span><span class="fpage" tagx="fpage" title="fpage">917</span><span class="lpage" tagx="lpage" title="lpage">927</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20194448">20194448</a></span></span></li> <li tag="ref"><a name="bib62" /><span class="label" tagx="label" title="label">62</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Vollenhoven</span><span class="given-names" tagx="given-names" title="given-names">R.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fleischmann</span><span class="given-names" tagx="given-names" title="given-names">R.M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Furst</span><span class="given-names" tagx="given-names" title="given-names">D.E.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lacey</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lehane</span><span class="given-names" tagx="given-names" title="given-names">P.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Longterm safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years</span><span class="source" tagx="source" title="source">J Rheumatol</span><span class="volume" tagx="volume" title="volume">42</span><span class="issue" tagx="issue" title="issue">10</span><span class="year" tagx="year" title="year">2015</span><span class="fpage" tagx="fpage" title="fpage">1761</span><span class="lpage" tagx="lpage" title="lpage">1766</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26276965">26276965</a></span></span></li> <li tag="ref"><a name="bib63" /><span class="label" tagx="label" title="label">63</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Winthrop</span><span class="given-names" tagx="given-names" title="given-names">K.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saag</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cascino</span><span class="given-names" tagx="given-names" title="given-names">M.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Long-term safety of rituximab in patients with rheumatoid arthritis: results of a five-year observational study</span><span class="source" tagx="source" title="source">Arthritis Care Res (Hoboken)</span><span class="volume" tagx="volume" title="volume">71</span><span class="issue" tagx="issue" title="issue">8</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">993</span><span class="lpage" tagx="lpage" title="lpage">1003</span></span></li> <li tag="ref"><a name="bib64" /><span class="label" tagx="label" title="label">64</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Joly</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maho-Vaillant</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Prost-Squarcioni</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span></span><span class="mixed-article-title" title="mixed-article-title">First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial</span><span class="source" tagx="source" title="source">Lancet</span><span class="volume" tagx="volume" title="volume">389</span><span class="issue" tagx="issue" title="issue">10083</span><span class="year" tagx="year" title="year">2017</span><span class="fpage" tagx="fpage" title="fpage">2031</span><span class="lpage" tagx="lpage" title="lpage">2040</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28342637">28342637</a></span></span></li> <li tag="ref"><a name="bib65" /><span class="label" tagx="label" title="label">65</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cooper</span><span class="given-names" tagx="given-names" title="given-names">N.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Davies</span><span class="given-names" tagx="given-names" title="given-names">E.G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thrasher</span><span class="given-names" tagx="given-names" title="given-names">A.J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin</span><span class="source" tagx="source" title="source">Br J Haematol</span><span class="volume" tagx="volume" title="volume">146</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2009</span><span class="fpage" tagx="fpage" title="fpage">120</span><span class="lpage" tagx="lpage" title="lpage">122</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19438506">19438506</a></span></span></li> <li tag="ref"><a name="bib66" /><span class="label" tagx="label" title="label">66</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Casulo</span><span class="given-names" tagx="given-names" title="given-names">C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maragulia</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zelenetz</span><span class="given-names" tagx="given-names" title="given-names">A.D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections</span><span class="source" tagx="source" title="source">Clin Lymphoma Myeloma Leuk</span><span class="volume" tagx="volume" title="volume">13</span><span class="issue" tagx="issue" title="issue">2</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">106</span><span class="lpage" tagx="lpage" title="lpage">111</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23276889">23276889</a></span></span></li> <li tag="ref"><a name="bib67" /><span class="label" tagx="label" title="label">67</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Makatsori</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kiani-Alikhan</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Manson</span><span class="given-names" tagx="given-names" title="given-names">A.L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Hypogammaglobulinaemia after rituximab treatmentâ€"incidence and outcomes</span><span class="source" tagx="source" title="source">QJM</span><span class="volume" tagx="volume" title="volume">107</span><span class="issue" tagx="issue" title="issue">10</span><span class="year" tagx="year" title="year">2014</span><span class="fpage" tagx="fpage" title="fpage">821</span><span class="lpage" tagx="lpage" title="lpage">828</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24778295">24778295</a></span></span></li> <li tag="ref"><a name="bib68" /><span class="label" tagx="label" title="label">68</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Assen</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Holvast</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Benne</span><span class="given-names" tagx="given-names" title="given-names">C.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab</span><span class="source" tagx="source" title="source">Arthritis Rheum</span><span class="volume" tagx="volume" title="volume">62</span><span class="issue" tagx="issue" title="issue">1</span><span class="year" tagx="year" title="year">2010</span><span class="fpage" tagx="fpage" title="fpage">75</span><span class="lpage" tagx="lpage" title="lpage">81</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20039396">20039396</a></span></span></li> <li tag="ref"><a name="bib69" /><span class="label" tagx="label" title="label">69</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nazi</span><span class="given-names" tagx="given-names" title="given-names">I.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kelton</span><span class="given-names" tagx="given-names" title="given-names">J.G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">LarchÃ©</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The effect of rituximab on vaccine responses in patients with immune thrombocytopenia</span><span class="source" tagx="source" title="source">Blood</span><span class="volume" tagx="volume" title="volume">122</span><span class="issue" tagx="issue" title="issue">11</span><span class="year" tagx="year" title="year">2013</span><span class="fpage" tagx="fpage" title="fpage">1946</span><span class="lpage" tagx="lpage" title="lpage">1953</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23851398">23851398</a></span></span></li> <li tag="ref"><a name="bib70" /><span class="label" tagx="label" title="label">70</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eichenfield</span><span class="given-names" tagx="given-names" title="given-names">L.F.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bieber</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Beck</span><span class="given-names" tagx="given-names" title="given-names">L.A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis</span><span class="source" tagx="source" title="source">Am J Clin Dermatol</span><span class="volume" tagx="volume" title="volume">20</span><span class="issue" tagx="issue" title="issue">3</span><span class="year" tagx="year" title="year">2019</span><span class="fpage" tagx="fpage" title="fpage">443</span><span class="lpage" tagx="lpage" title="lpage">456</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31066001">31066001</a></span></span></li> <li tag="ref"><a name="bib71" /><span class="label" tagx="label" title="label">71</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haberman</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Axelrad</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Covid-19 in immune-mediated inflammatory diseasesâ€"case series from New York [e-pub ahead of print]</span><span class="source" tagx="source" title="source">N Engl J Med</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1056/NEJMc2009567">10.1056/NEJMc2009567</a></span></span></li> <li tag="ref"><a name="bib72" /><span class="label" tagx="label" title="label">72</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gianfrancesco</span><span class="given-names" tagx="given-names" title="given-names">M.A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hyrich</span><span class="given-names" tagx="given-names" title="given-names">K.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gossec</span><span class="given-names" tagx="given-names" title="given-names">L.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries</span><span class="source" tagx="source" title="source">Lancet Rheumatol</span><span class="volume" tagx="volume" title="volume">2</span><span class="issue" tagx="issue" title="issue">5</span><span class="year" tagx="year" title="year">2020</span><span class="fpage" tagx="fpage" title="fpage">e250</span><span class="lpage" tagx="lpage" title="lpage">e253</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32309814">32309814</a></span></span></li> <li tag="ref"><a name="bib73" /><span class="label" tagx="label" title="label">73</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brenner</span><span class="given-names" tagx="given-names" title="given-names">E.J.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ungaro</span><span class="given-names" tagx="given-names" title="given-names">R.C.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gearry</span><span class="given-names" tagx="given-names" title="given-names">R.B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry [e-pub ahead of print]</span><span class="source" tagx="source" title="source">Gastroenterology</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1053/j.gastro.2020.05.032">10.1053/j.gastro.2020.05.032</a></span></span></li> <li tag="ref"><a name="bib74" /><span class="label" tagx="label" title="label">74</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Damiani</span><span class="given-names" tagx="given-names" title="given-names">G.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pacifico</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bragazzi</span><span class="given-names" tagx="given-names" title="given-names">N.L.</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Malagoli</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration [e-pub ahead of print]</span><span class="source" tagx="source" title="source">Dermatol Ther</span><span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/dth.13475">10.1111/dth.13475</a></span></span></li> </ul> </div> <div class="fn-group" title="fn-group"> <div class="fn-type-" title=""> <p id="ntpara0010">Drs Rosenbach and Merola contributed equally to the manuscript development (cosenior authors).</p> </div> <div class="fn-type-" title=""> <p id="ntpara0015">Funding sources: None.</p> </div> <div class="fn-type-" title=""> <p id="ntpara0020">Conflicts of interest: Dr Niaki has participated in an advisory boardÂ for Eli Lilly. Dr Anadkat is currently serving as consultant for Boehringer-Ingelheim, NovoCure, and OnQuality and asÂ anÂ investigator for Biogen, Lutris, AnaptyxBio, Boehringer-Ingelheim, OnQuality, Norvartis, ChemoCentryx, UCB Biopharma, and XBiotech. Dr Shinohara has been a principle investigator for clinical trials (Actelion, Soligenix, MiRAGEN). Dr Rosenbach, has served as a consultant for Merck, aTyr, Processa, and Janssen and has received research support from </p><div class="funding-source" title="funding-source">
Processa</div> and salary support from <i>JAMA Dermatology</i>. Dr Merola is a consultant and/or investigator for Merck, Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Drs Chen, Fox, Harp, Micheletti, Nambudiri, and Pasieka have no conflicts of interest to declare.<p /> </div> <div class="fn-type-" title=""> <p id="ntpara0025">IRB approval status: Not required.</p> </div> <div class="fn-type-" title=""> <p id="ntpara0075">Reprints not available from the authors.</p> </div> </div> </div>  </body></html>